BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu X, Deng C, Cao S, Gong J, Wang B, Hu C. Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats. Life Sciences 2015;128:72-8. [DOI: 10.1016/j.lfs.2015.01.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Feng X, Deng C, Liu L, Zeng Y, Hu CH. Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin. BMC Pharmacol Toxicol 2020;21:48. [PMID: 32605639 DOI: 10.1186/s40360-020-00427-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Su Y, Liu X, Lian J, Deng C. Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders. Pharmacological Research 2020;155:104703. [DOI: 10.1016/j.phrs.2020.104703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lian J, Deng C. The effects of antipsychotics on the density of cannabinoid receptors in selected brain regions of male and female adolescent juvenile rats. Psychiatry Research 2018;266:317-22. [DOI: 10.1016/j.psychres.2018.03.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Han M, Lian J, Su Y, Deng C. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats. J Psychopharmacol 2021;:2698811211050549. [PMID: 34694173 DOI: 10.1177/02698811211050549] [Reference Citation Analysis]
5 Asadi E, Abdouss M, Leblanc RM, Ezzati N, Wilson JN, Kordestani D. Synthesis, characterization and in vivo drug delivery study of a biodegradable nano-structured molecularly imprinted polymer based on cross-linker of fructose. Polymer 2016;97:226-37. [DOI: 10.1016/j.polymer.2016.05.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
6 Liu X, Wu Z, Lian J, Hu CH, Huang XF, Deng C. Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats. Sci Rep 2017;7:2762. [PMID: 28584269 DOI: 10.1038/s41598-017-02884-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
7 Vantaggiato C, Panzeri E, Citterio A, Orso G, Pozzi M. Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking. Trends Endocrinol Metab 2019;30:189-210. [PMID: 30718115 DOI: 10.1016/j.tem.2019.01.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
8 Liu X, Lian J, Hu C, Deng C. Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways. Pharmacological Research 2015;100:36-46. [DOI: 10.1016/j.phrs.2015.07.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
9 Chen L, Zhang YH, Zou Q, Chu C, Ji Z. Analysis of the chemical toxicity effects using the enrichment of Gene Ontology terms and KEGG pathways. Biochim Biophys Acta 2016;1860:2619-26. [PMID: 27208425 DOI: 10.1016/j.bbagen.2016.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
10 Stefanidis A, Watt MJ, Cowley MA, Oldfield BJ. Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide. Neuropharmacology 2017;123:55-66. [PMID: 28400260 DOI: 10.1016/j.neuropharm.2017.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
11 Bagher AM, Young AP, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments. J Neurosci Res 2020;98:2496-509. [PMID: 32881145 DOI: 10.1002/jnr.24716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Li Y, Zhao X, Feng X, Liu X, Deng C, Hu CH. Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα-SREBP Pathway in 3T3-L1 Cells. Int J Mol Sci 2016;17:E1865. [PMID: 27834848 DOI: 10.3390/ijms17111865] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
13 Liu XM, Zhao XM, Deng C, Zeng YP, Hu CH. Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway. Acta Pharmacol Sin 2019;40:1049-57. [PMID: 30728467 DOI: 10.1038/s41401-019-0212-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
14 Jiang T, Zhang Y, Bai M, Li P, Wang W, Chen M, Ma Z, Zeng S, Zhou H, Jiang H. Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis. Toxicology Letters 2019;316:183-93. [DOI: 10.1016/j.toxlet.2019.08.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Del Campo A, Bustos C, Mascayano C, Acuña-Castillo C, Troncoso R, Rojo LE. Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance. Front Endocrinol (Lausanne) 2018;9:144. [PMID: 29740394 DOI: 10.3389/fendo.2018.00144] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Babanejad N, Nabid MR, Farhadian A, Dorkoosh F, Zarrintaj P, Saeb MR, Mozafari M. Sustained delivery of olanzapine from sunflower oil-based polyol-urethane nanoparticles synthesised through a cyclic carbonate ring-opening reaction. IET Nanobiotechnol 2019;13:703-11. [PMID: 31573539 DOI: 10.1049/iet-nbt.2018.5440] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
17 Lian J, Deng C. The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats. Pharmacol Biochem Behav 2020;191:172878. [PMID: 32112786 DOI: 10.1016/j.pbb.2020.172878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Sylvester E, Yi W, Han M, Deng C. Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. Pharmacol Biochem Behav 2020;199:173064. [PMID: 33127383 DOI: 10.1016/j.pbb.2020.173064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Weston-Green K, Babic I, de Santis M, Pan B, Montgomery MK, Mitchell T, Huang XF, Nealon J. Disrupted sphingolipid metabolism following acute clozapine and olanzapine administration. J Biomed Sci 2018;25:40. [PMID: 29720183 DOI: 10.1186/s12929-018-0437-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]